Skip to main content
SpringerLink
Log in

Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer

  • Chapter
  • First Online:
Advancements in Clinical Research

Part of the book series: Advances in Experimental Medicine and Biology ((NR,volume 952))

Abstract

Hepatocyte growth factor (HGF) is involved in tumorigenesis, interleukin-20 (IL-20) is an inhibitor of angiogenesis, and interleukin-22 (IL-22) stimulates tumor growth. The aim of this study was to determine the level of HGF, IL-20, and IL-22 in both serum and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients before onset of chemotherapy, the nature of the interrelationships between these markers, and their prognostic significance regarding post-chemotherapy survival time. We studied 46 NSCLC patients and 15 healthy subjects as a control group. We found significantly higher serum levels of HGF and IL-22 in the NSCLC patients than those in controls [pg/ml: HGF – 1911 (693–6510) vs. 1333 (838–3667), p = 0.0004; IL-22 – 10.66 (1.44–70.34) vs. 4.69 (0.35–12.29), p = 0.0007]. In contrast, concentrations of HGF and IL-22 in BALF were lower in NSCLC patients than those in controls [pg/ml: HGF – 72 (6–561) vs. 488 (14–2003), p = 0.0002; IL-22 – 2.28 (0.70–6.52) vs. 3.72 (2.76–5.64), p = 0.002]. In the NSCLC patients, there was a negative correlation between the serum level of IL-20 and time to tumor progression (r = −0.405, p = 0.04) and between the serum level of HGF and survival time (r = −0.41, p = 0.005). In addition, a higher serum level of HGF and a higher BALF level of IL-22 in patients were linked with a shorter overall survival. We conclude that HGF, IL-20, and IL-22 in the serum and BALF of NSCLC patients before chemotherapy may be a prognostic of cancer progression.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Baird AM, Gray SG, O’Byrne KJ (2011) IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur J Cancer 47:1908–1918

    Article  CAS  PubMed  Google Scholar 

  • Cho KA, Kim JY, Woo SY, Park HJ, Lee KH, Pae CU (2012) Interleukin-17 and Interleukin-22 induced proinflammatory cytokine production in keratinocytes via inhibitor of nuclear factor kB kinase-α expression. Ann Dermatol 24:398–405

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dąbrowska M, Skoneczny M, Rode W (2011) Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol 32:965–976

    Article  PubMed  PubMed Central  Google Scholar 

  • Dudakov JA, Hanash AM, Jenq RR, Young LF, Ghosh A, Singer NV, West ML, Smith OM, Holland AM, Tsai JJ, Boyd RL, van den Brink MR (2012) Interleukin-22 drives endogenous thymic regeneration in mice. Science 336:91–95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garajová I, Giovannetti E, Biasco G, Peters GJ (2015) c-Met as a target for personalized therapy. Transl Oncogenomics 7:13–31

    PubMed  PubMed Central  Google Scholar 

  • Gibot L, Galbraith T, Kloos DS, Lacroix DA, Auger FA, Skobe M (2016) Cell-based approach for 3D reconstruction of lymphatic capillaries in vitro reveals distinct functions of HGF and VEGF-C in lymphangiogenesis. Biomaterials 78:129–139

    Article  CAS  PubMed  Google Scholar 

  • Heuzé-Vourc’h N, Liu M, Dalwadi H, Baratelli FE, Zhu L, Goodglick L, Põld M, Sharma S, Ramirez RD, Shay JW, Minna JD, Strieter RM, Dubinett SM (2005) IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun 333:470–475

    Article  PubMed  Google Scholar 

  • Heynen GJ, Fonfara A, Bernards R (2014) Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle 13:3808–3817

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS (2012) Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol 188:1981–1991

    Article  CAS  PubMed  Google Scholar 

  • Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348:74–80

    Article  CAS  PubMed  Google Scholar 

  • Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, Düwell P, Lindner M, Koch I, Heidegger S, Rothenfuer S, Schnurr M, Huber RM, Wilczak W, Endres S (2013) Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol 8:1032–1042

    Article  CAS  PubMed  Google Scholar 

  • Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907

    Article  CAS  PubMed  Google Scholar 

  • Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim JH, Choi YH, Kim WJ, Moon SK (2013) Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-kB) activation by inducing the up-regulation of p21(WAF1) protein expression. J Biol Chem 288:5539–5552

    Article  CAS  PubMed  Google Scholar 

  • Lim C, Savan R (2014) The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev 25:257–271

    Article  CAS  PubMed  Google Scholar 

  • Masuya D, Huang C, Liu D, Nakashima T, Kameyama K, Haba R, Ueno M, Yokomise H (2004) The tumour-stromal interaction between intratumoral c-MET and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small cell lung cancer patients. Br J Cancer 90:1555–1562

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape. Curr Opin Immunol 27:16–25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pan B, Wang R, Huang Y, Garfield D, Zhang J, Chen H (2015) HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma. Onco Targets Ther 25:1185–1191

    Article  Google Scholar 

  • Park O, Wang H, Weng H, Feigenbaum L, Li H, Yin S, Ki SH, Yoo SH, Dooley S, Wang FS, Young HA, Gao B (2011) In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 54:252–261

    Article  PubMed  PubMed Central  Google Scholar 

  • Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members and Participating Institutions (2014) The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol 9:1618–1624

    Article  CAS  PubMed  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2002) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  Google Scholar 

  • Ujiie H, Tomida M, Akiyama H, Nakajima Y, Okada D, Yoshino N, Takiguchi Y, Tanzawa H (2012) Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 32:3251–3258

    CAS  PubMed  Google Scholar 

  • Wislez M, Rabbe N, Marchal J, Milleron B, Crestani B, Mayaud C, Antoine M, Soler P, Cadranel J (2003) Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death. Cancer Res 63:1405–1412

    CAS  PubMed  Google Scholar 

  • Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z (2008) Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 14:6432–6439

    Article  CAS  PubMed  Google Scholar 

  • Ziesché E, Bachmann M, Kleinert H, Pfeilschifter J, Mühl H (2007) The interleukin-22/STAT3 pathway potentiates expression of inducible nitric-oxide synthase in human colon carcinoma cells. J Biol Chem 282:16006–16015

    Article  PubMed  Google Scholar 

Download references

Conflicts of Interest

The authors had no conflicts of interest to declare in relation to this article.

Author information

Authors and Affiliations

  1. Department of Lung Diseases, Medical University of Bialystok, 14 Zurawia Street, 15-540, Bialystok, Poland

    W. Naumnik, M. Ossolińska & E. Chyczewska

  2. Department of Clinical Molecular Biology, Medical University of Bialystok, Bialystok, Poland

    W. Naumnik

  3. First Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Bialystok, Bialystok, Poland

    B. Naumnik

  4. Department of Histology and Embryology, Medical University of Bialystok, Bialystok, Poland

    W. Niklińska

Authors
  1. W. Naumnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Naumnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. Niklińska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Ossolińska
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Chyczewska
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Naumnik .

Editor information

Editors and Affiliations

  1. Public Higher Medical Professional School in Opole, Institute of Nursing, Opole, Poland

    Mieczyslaw Pokorski

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Naumnik, W., Naumnik, B., Niklińska, W., Ossolińska, M., Chyczewska, E. (2016). Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer. In: Pokorski, M. (eds) Advancements in Clinical Research. Advances in Experimental Medicine and Biology(), vol 952. Springer, Cham. https://doi.org/10.1007/5584_2016_66

Download citation

Publish with us

Policies and ethics

Search

Navigation